Skip to main content
Premium Trial:

Request an Annual Quote

BioFocus DPI, Clontech Laboratories

Premium
BioFocus DPI this week launched a drug-discovery service called PrimePath, which screens small molecules using disease-relevant human primary cells.
 
Clients will have the opportunity to screen compounds against cellular disease models that have already been developed by BioFocus and are available “off the shelf,” the company said. BioFocus said that it can also work with clients to develop new cellular disease models that mimic a specific disease process for a defined therapeutic area.
 

 
Clontech Laboratories this week announced that it is making the DsRed-monomer fluorescent protein available to for-profit entities for research and commercial use. Previously, Ds-Red was only available to not-for-profit institutions.
 
Ds-Red monomer is a highly engineered monomeric form of the normally tetrameric Discosoma sp. red fluorescent protein, and is part of Clontech’s Living Colors line of fluorescent proteins. The red-shifted emission spectra and monomeric form of Ds-Red makes it ideal as a fusion tag, Clontech said.
 

 
Note: A number of new cell-based assay products were released at the Society for Biomolecular Sciences annual meeting held this week in Seattle, but could not be included in this issue due to time constraints. Look in next week’s issue of CBA News for a full product roundup from the show.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more